CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Alkem launches Favipiravir for COVID-19 treatment under brand Alfluenza
DSIJ Intelligence
/ Categories: Trending, DSIJ News

Alkem launches Favipiravir for COVID-19 treatment under brand Alfluenza

Alkem Laboratories Limited, a leading Indian pharmaceutical company announced the launch of Favipiravir under the brand name of ‘Alfluenza’ on Wednesday.

Reacting to this news, the share of Alkem Laboratories traded nearly 2 per cent higher during Thursday’s early session.

As the COVID-19 cases continue to mount globally, India is significantly affected with around 50,000 new cases being added on a daily basis. Alkem Laboratories launched Alfluenza in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by Drug Controller General of India (DCGI) for the restricted emergency use in India.

Glenmark Pharma was the first pharmaceutical company to launch Favipiravir under the brand name of ‘FabiFlu’ at Rs 105 which was later cut down to Rs 75. After Glenmark, companies like Cipla, Lupin and Sun Pharmaceutical Industries also launched their own version of Favipiravir tablets. Lupin’s ‘Covihalt’ is priced at Rs 49 per tablet, while Sun Pharma’s ‘FluGuard’ is priced as low as Rs 35 per tablet, so far the cheapest in India.

At around 10.42 am on Thursday, the share of Alkem Laboratories was trading at Rs 2,883 with gains of 1.44 per cent. On August 4, it touched a new 52-week high value of Rs 2,975.65 while its 52-week low is Rs 1,682.1 on BSE.

Previous Article Ten stocks close to their 52-week high
Next Article Gilt Funds: Should you invest in them now?
Print
2841 Rate this article:
4.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR